Adenovirus (RGDCRAdCOX2F)

This study is testing a modified virus (called RGDCRAdCOX2F) injected directly into pancreatic tumors using an endoscopic ultrasound procedure. The virus is engineered to selectively infect and kill cancer cells. This is an early-phase study focused on safety in patients with pancreatic cancer confined to the pancreas and nearby lymph nodes. **You may be eligible if...** - You are 18 or older - You have been diagnosed with pancreatic adenocarcinoma (confirmed by tissue biopsy) that is confined to the pancreas and regional lymph nodes - You have normal heart and lung function - You may have had one prior treatment (neo-adjuvant therapy), but at least 4 weeks must have passed since your last dose - Your tumor is accessible via endoscopic ultrasound - You are willing and able to use effective contraception if of childbearing potential **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have another type of pancreatic tumor (such as a neuroendocrine tumor) or cancer of the bile duct or duodenum - Your tumor is located near vital structures (airways, major blood vessels, or spinal cord) where swelling could be dangerous - You have HIV or other serious immune conditions Talk to your doctor to see if this trial is right for you.